Tortoise Or Hare? How Biosafety Assurance Can Be Both Rapid And Purposeful Getting You To The Finish Line First.
Source: MilliporeSigma
In this webinar we will discuss how the advancement of bioprocessing and the rise of novel treatment modalities such as viral vectors, as well as the urgent need for SARS-CoV-2 treatments and vaccines have driven the industry to adopt rapid alternatives. By illustrating the reasons behind the move to faster methods and discussing the wider benefits these can bring we hope to do our bit to drive change within this change resistant environment, and help our customers win the race to market.
In this webinar, you will get an overview about:
- Regulatory landscape and acceptance to alternate methods
- Considerations when looking to accelerate cell line characterization and lot release testing
- Overview of rapid technologies that are being accepted by the regulators for biosafety testing
VIEW THE WEBINAR!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Biosimilar Development? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more